P845 ATLAS 1: the first Phase 3 study evaluating the new lipoglycopeptide, telavancin, for the treatment of patients with complicated skin and skin structure infections

✍ Scribed by G.R. Corey; M.E. Stryjewski; W.D. O'Riordan; V.G. Fowler Jr; D.P. Ross; A. Hopkins; M.M. Kitt; S.L. Barriere

• Book ID: 119564827
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 86 KB
• Volume: 29
• Category: Article
• ISSN: 0924-8579
• DOI: 10.1016/s0924-8579(07)70686-6